

Special Issue

Advanced Neuroendocrine Tumors

Message from the Guest Editor

Neuroendocrine tumors (NETs) are a clinically heterogeneous group of cancers, arising from the cells of endocrine glands (pituitary, adrenals and parathyroid), as well as neuroendocrine cells in the diffuse neuroendocrine system. Whilst considered to be a rare disease, the incidence of NETs has increased dramatically over the past 30 years, and unlike most other solid tumors, the incidence continues to rise. Recently, there have been exciting changes in the management of NETs, with the introduction of peptide receptor radiotherapy, which has changed the treatment landscape, and there are a number of clinical trials investigating the utility of immunotherapy in this field. In this Special Issue, we will bring together expertise in epigenetics, imaging and immunotherapy in addressing the evolving field of NETs.

Guest Editor

Dr. Rohini Sharma

Clinical Pharmacology and Medical Oncology, Imperial College London, London, UK

Deadline for manuscript submissions

closed (20 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/55883

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)